Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2361${count})

  • Research Grant, 2019
    Longitudinal Examination of Problems that Bother People with Parkinson’s

    Study Rationale:
    Using the Fox Insight research platform, we extracted and analyzed reports in patients’ own words about what problems bother them and how these problems affect their daily functioning...

  • Therapeutic Pipeline Program, 2019
    Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic

    Study Rationale:
    There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune...

  • Research Grant, 2019
    The Synaptic Vesicle Cycle in Parkinson’s Disease

    Study Rationale:
    Many of the proteins implicated in Parkinson’s disease appear to have a role at the nerve terminal, presumably in neurotransmitter release. However, the function of most has remained...

  • GBA Biology and Therapies, 2019
    Expression of GCase throughout Brain Vasculature for Degradation of Alpha-synuclein Aggregates

    Study Rationale:                   
    Alpha-synuclein toxicity is caused by progressive accumulation of this protein in cells. Alpha-synuclein protein aggregation is helped along by impaired lysosomes...

  • Research Grant, 2019
    Validation of Microglial CRAC Channels as a Therapeutic Target for Parkinson’s Disease

    Study Rationale:
    Inflammation of the central nervous system mediated by microglial cells is a major feature of Parkinson’s disease. Vivreon Biosciences is developing Parkinson’s disease therapeutics...

  • Research Grant, 2019
    Determining the Level of LRRK2 Inhibition Required for Therapeutic Efficacy

    Study Rationale:
    While inhibitors of LRRK2 activity are currently in clinical trials for the treatment of Parkinson’s disease, the minimum requirement of target engagement to significantly modify...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.